Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Assertio Holdings, Inc.ASRT · Entity 37706 | Director · CEO | May 31, 2025 | June 03, 2025 |
| Nasus Pharma LtdNSRX · Entity 7254 | Director · Chief Executive Officer | July 27, 2026 | July 31, 2026 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP, North America Commercial | March 04, 2021 | March 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Assertio Holdings, Inc.
Report date May 31, 2025 · Filed June 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 128,955.462 |
Ending reported balance
After 2025-05-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-31 · Exercise / conversion · Acquired 166,665 · Balance 178,371.462 Row 2 · 2025-05-31 · Tax withholding · Disposed 49,416 · Balance 128,955.462 F1: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2027-05-31 | Direct | 333,335 |
Reported balance
After 2025-05-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-31 · Exercise / conversion · Disposed 166,665 · Balance 333,335 F2: Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock. F4: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F3: One-third of these restricted stock units vests on each of May 31, 2025, 2026 and 2027, assuming continued employment through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units.
F2: Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock.
F3: One-third of these restricted stock units vests on each of May 31, 2025, 2026 and 2027, assuming continued employment through the applicable vesting date.
F4: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
Nasus Pharma Ltd
Report date July 27, 2026 · Filed July 31, 2026
This filing explicitly reported no securities owned.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date March 04, 2021 · Filed March 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 14,868.486 |
Last balance in matching sequence
After 2021-03-05 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2021-03-04 · Sale · Disposed 703 · Balance 14,868.486 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Row 2 · 2021-03-04 · Exercise / conversion · Acquired 18,905 · Balance 33,773.486 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Row 3 · 2021-03-04 · Sale · Disposed 7,469 · Balance 26,304.486 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.5100 to $10.6900, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2021-03-05 · Sale · Disposed 11,436 · Balance 14,868.486 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.5000 to $10.5775, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 37,811 |
Reported balance
After 2021-03-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-04 · Exercise / conversion · Disposed 18,905 · Balance 37,811 F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 109,315 |
Reported balance
After 2021-03-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-03-05 · Grant · Acquired 109,315 · Balance 109,315 F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8: Restricted share units were granted on March 5, 2021, with 27,328 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 27,331 vesting on March 5, 2025. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.5100 to $10.6900, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.5000 to $10.5775, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023.
F8: Restricted share units were granted on March 5, 2021, with 27,328 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 27,331 vesting on March 5, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2018 Filed Sep 20, 2018 20:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-051780 · doc4.xml · derivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,241 Underlying: Ordinary Shares · 1,241 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on September 18, 2017, with 1,241 vesting on each of September 18, 2018 and September 18, 2019. F4 · derivative.expiration_date: Restricted share units were granted on September 18, 2017, with 1,241 vesting on each of September 18, 2018 and September 18, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,241 | $23.71 | $29,420.39 |
DisclosureSEC source: 0001209191-18-051780 · doc4.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,388.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.640 to $23.735, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,241 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-051780 · doc4.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,629.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 20:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,179 | $17.88 | $21,078.16 |
DisclosureSEC source: 0001209191-18-020864 · doc4.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,388.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.83 to $17.925, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020864 · doc4.xml · derivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,358 Underlying: Ordinary Shares · 1,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 1,179 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F4 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 1,179 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-020864 · doc4.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,567.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:34 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 738 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-019567 · doc4.xml · derivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 738 Underlying: Ordinary Shares · 738 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 12, 2015, with 738 vesting on each of March 12, 2018 and March 12, 2019. F4 · derivative.expiration_date: Restricted share units were granted on March 12, 2015, with 738 vesting on each of March 12, 2018 and March 12, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:34 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 738 | $19.49 | $14,382.88 |
DisclosureSEC source: 0001209191-18-019567 · doc4.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,388.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.46 to $19.50, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:34 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 738 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-019567 · doc4.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,126.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 705 | $19.38 | $13,662.90 |
DisclosureSEC source: 0001209191-18-017230 · doc4.xml · nonDerivative · entry 3 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,388.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Tax withholdingOrdinary Shares | 461 | $19.38 | $8,934.18 |
DisclosureSEC source: 0001209191-18-017230 · doc4.xml · nonDerivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,093.486 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 21:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017230 · doc4.xml · derivative · entry 4 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,498 Underlying: Ordinary Shares · 1,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,166 vesting on each of March 3, 2018, March 3, 2019, March 3, 2020 and March 3, 2021. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,166 vesting on each of March 3, 2018, March 3, 2019, March 3, 2020 and March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 21:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-017230 · doc4.xml · nonDerivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,554.486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 48,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009201 · doc4.xml · derivative · entry 2 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,361 Underlying: Ordinary Shares · 48,361 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022. F4 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantStock Options (right to buy) · Derivative | 123,288 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001209191-18-009201 · doc4.xml · derivative · entry 1 O'Grady Brendan P. · CIK 0001726533 · EVP, North America Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,288 Underlying: Ordinary Shares · 123,288 shares Expires 2028-02-08 F1 · derivative.exercise_date: Stock options were granted on February 9, 2018, with 41,096 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.